Penelope Kay-Fedorov

Dr. Penelope Kay-Fedorov

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JZJasmin Zischke
Jasmin Zischke
PMPanagiota Mamareli
Panagiota Mamareli
CPClaudia Pokoyski
Claudia Pokoyski
IGIldar Gabaev
Ildar Gabaev
SBSabine Buyny
Sabine Buyny
PKPenelope Kay-Fedorov
Penelope Kay-Fedorov
Human Cytomegalovirus (HCMV) is a widespread pathogen, infection with which can cause severe disease for immunocompromised individuals. The complex changes wrought on the host’s immune system during both productive and latent HCMV infection are well known. Infected cells are masked and manipulated and uninfected immune cells are also affected; peripheral blood mononuclear cell (PBMC) proliferation is reduced and cytokine profiles altered. Levels increase of the anti-inflammatory cytokine IL-10, which may be important for the establishment of HCMV infections and is required for the development of high viral titres by murine cytomegalovirus. The mechanisms by which HCMV affects T cell IL-10 secretion are not understood. We show here that treatment of PBMC with purified pUL11 induces IL-10 producing T cells as a result of pUL11 binding to the CD45 phosphatase on T cells. IL-10 production induced by HCMV infection is also in part mediated by pUL11. Supernatants from pUL11 treated cells have anti-inflammatory effects on untreated PBMC. Considering the mechanism, CD45 can be a positive or negative regulator of TCR signalling, depending on its expression level, and we show that pUL11 also has concentration dependent activating or inhibitory effects on T cell proliferation and on the kinase function of the CD45 substrate Lck. pUL11 is therefore the first example of a viral protein that can target CD45 to induce T cells with anti-inflammatory properties. It is also the first HCMV protein shown to induce T cell IL-10 secretion. Understanding the mechanisms by which pUL11-induced changes in signal strength influence T cell development and function may provide the basis for the development of novel antiviral treatments and therapies against immune pathologies. Human cytomegalovirus (HCMV) infects from 45% to 100% of people worldwide, depending on local socio-economic factors. Although usually harmless in healthy individuals, infection with HCMV can cause severe disease in people with weakened or immature immune systems such as transplant recipients and newborns. The establishment and maintenance of life-long infections by HCMV are greatly aided by its ability to modulate the host’s immune system during both active and latent infection; infected cells are masked and both infected and uninfected immune cells have their functions manipulated. One effect of HCMV infection is the induction of the cytokine IL-10, a secreted protein that suppresses many antiviral responses. Here, we identify a viral protein, pUL11, which can induce IL-10 expression by T cells and reduce the production of mediators of inflammation. pUL11 interacts with CD45, an immune system regulator that controls the sensitivity of T cells and has been linked to IL-10 production. We show that pUL11 can likewise affect T cell responses to stimuli, depending on its concentration, and suggest that this underlies its functions. pUL11 is the first viral protein known with this mechanism and further understanding of its effects may lead to the development of novel antiviral therapies and also help in the treatment of immune system disorders.

15 May 2011 in Journal of Virology
Verified
Journal Article
Closed access
ALAndrea Loewendorf
Andrea Loewendorf
LSLars Steinbrueck
Lars Steinbrueck
CPChristoph Peter
Christoph Peter
ABAndreas Busche
Andreas Busche
CBChris A. Benedict
Chris A. Benedict
PKPenelope Kay-Fedorov
Penelope Kay-Fedorov
Cytomegaloviruses (CMV) utilize a variety of immunomodulatory strategies to facilitate the establishment of lifelong persistence in their infected hosts. We show that the mouse CMV (MCMV) m155 open reading frame (ORF) is required for the posttranscriptional inhibition of CD40 expression in infected antigen-presenting cells. Consistent with the known importance of CD40-mediated costimulation of T cells, a m155-deficient virus induces enhanced MCMV epitope-specific CD4 T cell responses.

23 March 2015 in Viruses
Verified
Journal Article
Open access
PDF file
NTNadine Thiel
Nadine Thiel
JZJasmin Zischke
Jasmin Zischke
EEEndrit Elbasani
Endrit Elbasani
PKPenelope Kay-Fedorov
Penelope Kay-Fedorov
MMMartin Messerle
Martin Messerle
The receptor tyrosine phosphatase CD45 is expressed on the surface of almost all cells of hematopoietic origin. CD45 functions are central to the development of T cells and determine the threshold at which T and B lymphocytes can become activated. Given this pivotal role of CD45 in the immune system, it is probably not surprising that viruses interfere with the activity of CD45 in lymphocytes to dampen the immune response and that they also utilize this molecule to accomplish their replication cycle. Here we report what is known about the interaction of viral proteins with CD45. Moreover, we debate putative interactions of viruses with CD45 in myeloid cells and the resulting consequences—subjects that remain to be investigated. Finally, we summarize the evidence that pathogens were the driving force for the evolution of CD45.

20 December 2022 in mBio
Verified
Journal Article
Open access
SOSamuel A. Osanyinlusi
Samuel A. Osanyinlusi
JZJasmin Zischke
Jasmin Zischke
RJRoland Jacobs
Roland Jacobs
EWEva M. Weissinger
Eva M. Weissinger
TSThomas Schultz
Thomas Schultz
PKPenelope Kay-Fedorov
Penelope Kay-Fedorov
Human cytomegalovirus (HCMV) is adept at avoiding its host’s immune defenses, both by evading detection and by directly inhibiting immune cells. This can lead to a loss of control of the infection, and dangerous disease can result, particularly in cases in which an individual’s immune system is immature, weak, or suppressed.


8 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
MHMedizinische Hochschule Hannover
Medizinische Hochschule Hannover
LSLisa Marie Schulz
Lisa Marie Schulz
DBDébora Basílio-Queirós
Débora Basílio-Queirós
MSMichael Stadler
Michael Stadler
PKPenelope Kay-Fedorov
Penelope Kay-Fedorov
Viral infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in patients with delayed immune reconstitution or prolonged immunosuppression. Although antiviral drugs have substantially reduced the incidence of viral disease, their use is limited by toxicity, resistance, and the inability to restore long-term antiviral immunity. Adoptive transfer of virus-specific T cells represents a targeted immunotherapeutic strategy to re-establish pathogen-specific immune responses while minimizing the risk of graft-versus-host disease (GvHD). This review focuses on the development and clinical application of adoptive virus-specific T cell therapy after allogeneic HSCT, with particular emphasis on cytomegalovirus (CMV). We summarize the evolution of adoptive antiviral T cell therapy, compare current manufacturing and selection strategies, and critically review available clinical evidence regarding efficacy, persistence, safety, and alloreactivity. In addition to CMV-directed products, we discuss approaches targeting Epstein–Barr virus (EBV), adenovirus (AdV), and other clinically relevant pathogens in the context of multipathogen-specific T cell products and third-party donor approaches. We further address current knowledge on immune monitoring, factors influencing antiviral immune reconstitution, as well as practical challenges that still limit broader clinical use. Finally, we discuss emerging strategies to improve product standardization, availability, and integration of adoptive T cell therapy with modern antiviral prophylaxis and graft-engineering approaches.